Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Filana Therapeutics, Inc.

NASDAQ: FLNA · Life Sciences · 8 alerts · CIK 1069530

Share price
$0.4700Close, Nov 16
Market cap
$23.6M
Shares outstanding
50.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Filana Therapeutics, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Filana Therapeutics Q3 2026 Results: Net Loss of $10.7M, Loss Narrows

Filana Therapeutics reported a net loss of $10.7 million for the third quarter of 2026, with a significant reduction in nine-month operating expenses compared to the prior year. The company received a Nasdaq deficiency notice regarding its share price but maintains a cash position of $78.2 million, which management believes is sufficient for at least the next 12 months.

Key figure
Net loss $10.7M
8:11 AM ET 8-K
Financial Results

Filana Therapeutics Financial Results

Filana Therapeutics reported Q3 2026 financial results, including a net loss of $10.7 million and a cash balance of $47.0 million. The company announced that patient screening for its Phase 2a study of simufilam in TSC-related epilepsy is expected to begin by Q1 2027 following the recent lifting of an FDA clinical hold.

“Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expected to begin by the first quarter of 2027.”

Rick Barry, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.